Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
Open Access
- 5 October 2018
- journal article
- research article
- Published by Springer Nature in BMC Ophthalmology
- Vol. 18 (1) , 1-7
Abstract
To report the switch rate of conventional immunosuppressive (CIS) therapies to the biological agents (BA) in patients with refractory Behcet’s uveitis (BU). In this retrospective study, clinical records were reviewed of 76 patients’ 116 eyes presenting with BU who had been treated with immunosuppressive drug therapy. Mann Whitney U test was used for the intergroup comparisons of parameters without normal distribution as well as calculation of descriptive statistical methods (mean, standard deviation, median, frequency and rate). Wilcoxon Signed Ranks test was used for the intragroup comparisons of parameters without normal distribution. Pearson’s Chi-Square test and Fisher-Freeman-Halton test were used for the comparisons of qualitative data. Except for one, all patients were first treated with CIS regimens for BU. Thirty-one patients (41.3%) who were unresponsive to CIS regimens were switched to IFNα2a therapy. After that, eight of these cases were switched to the anti-TNF-α treatments. The presence of initial ocular complications were found to be statistically higher in BA treated patients than the CIS treated cases (p < 0.001). Both in CIS treated and in BA treated cases, an increase in visual acuity (VA) was observed during the last examination compared to the initial examination and was significant (p < 0.001 and p = 0.018, respectively). CIS treatment was found to be effective and safe, as suggested in the management guidelines for severe BU. Biological therapy was also found effective for the improvement of the VA. We observed that 58.7% of cases could be treated with strong immunosuppressive therapies, however, nearly half of the patients could have lost their VA if BAs were not existent. During the treatment course of severe cases with BU, classical therapy stage must still be protected as the first-line therapy due to the their reasonable activity and safety.Keywords
This publication has 12 references indexed in Scilit:
- Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 PatientsOphthalmology, 2012
- Long-term Efficacy and Safety of Low-Dose and Dose-Escalating Interferon Alfa-2a Therapy in Refractory Behçet UveitisArchives of Ophthalmology (1950), 2011
- Safety and Effectiveness of Interferon Alpha-2a in Treatment of Patients with Behçet's Uveitis Refractory to Conventional TreatmentsOphthalmology, 2010
- Long-term Efficacy and Safety of Low-dose Interferon Alpha2a Therapy in Severe Uveitis Associated With Behçet DiseaseAmerican Journal of Ophthalmology, 2008
- Behçet's disease: Ocular effects and treatmentProgress in Retinal and Eye Research, 2008
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- The use of interferon α in behçet disease: review of the literatureSeminars in Arthritis and Rheumatism, 2004
- Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.1990
- Beh et's syndrome: Treatment with recombinant leukocyte alpha-interferonArchives of Dermatological Research, 1986
- Behçet's diseaseSurvey of Ophthalmology, 1982